Edward Hurwitz
CIK 1211840 · last filed 2026-06-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MGNX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DYN | Director | 91,081 | $16.05 | $1.46M | $0 | 7 | 2026-06-09 |
| MGNX | Director | 1,752,820 | $1.99 | $3.48M | -$11.19M | 18 | 2026-05-20 |
| APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Director | 0 | $0.39 | $0 | $0 | 12 | 2022-12-01 |
| Tvardi Therapeutics, Inc. (CARA) Delisted | Director | 1,200 | $15.96 | $19.2K | $1.24M | 2 | 2014-02-05 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | Director | 826 | $18.62 | $15.4K | -$4.49M | 9 | 2013-07-02 |
| Molecular Templates, Inc. (THLD) Delisted | 139,693 | — | — | $500.0K | 1 | 2009-10-06 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| DYN | MPM BioVentures 2018 See footnote |
91,081 | 100.0% | 2020-09-23 |
| Total | 91,081 | |||
| MGNX | Direct | 47,824 | 2.7% | 2026-05-20 |
| See Footnote | 1,704,996 | 97.3% | 2014-02-18 | |
| Total | 1,752,820 | |||
| AGTC | Direct | 0 | — | 2022-12-01 |
| By Hurwitz/Lichtenfeld Revocable Trust | 0 | — | 2022-12-01 | |
| Total | 0 | |||
| CARA | Alta BioPharma Partners III, L.P. See Footnote |
1,200 | 100.0% | 2014-02-05 |
| Total | 1,200 | |||
| SNSS | See Footnote | 826 | 100.0% | 2010-07-02 |
| Total | 826 | |||
| No longer reported | ||||
| By Fund | 0 | — | last 2009-12-16 | |
| THLD | Direct | 130,902 | 93.7% | 2009-10-06 |
| See footnotes | 8,791 | 6.3% | 2009-10-06 | |
| Total | 139,693 | |||
Recent Filings · Page 2 of 5
50 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-12-01 | APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Mixed | −27,472 | $0 | EDGAR |
| 2022-06-06 | DYN | Grant (A) | — | $0 | EDGAR |
| 2022-05-23 | MGNX | Grant (A) | — | $0 | EDGAR |
| 2021-12-02 | APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-27 | DYN | Grant (A) | — | $0 | EDGAR |
| 2021-05-17 | MGNX | Grant (A) | — | $0 | EDGAR |
| 2020-12-18 | APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-09-23 | DYN | Mixed | +4,951,303 | $0 | EDGAR |
| 2020-05-15 | MGNX | Grant (A) | — | $0 | EDGAR |
| 2019-12-06 | APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).